drugset / Trial / NCT02792686

ABX464 First in Man Study

NCT02792686

Phase 1 Completed 24 enrolled Abivax S.A.
NaSingle-groupOpen-labelTreatment

Summary

This study is an open label, parallel group, single ascending dose, exploratory study performed in a single site (Centre Cap, Montpellier, France).

Timeline

Start
2014-03
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Obefazimod Small molecule 50 mg Oral
Subject Obefazimod Small molecule 100 mg Oral
Subject Obefazimod Small molecule 150 mg Oral
Subject Obefazimod Small molecule 200 mg Oral

Indications

No indication recorded.